The Patent Finder

REMD Biotherapeutics, Inc.

12 patents currently held · Updated Nov 18, 2026
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Jun 2035
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Oct 21, 2027
    The maintenance fee for Methods for treating type 1 diabetes using glucagon receptor antagonistic antibodies (US 10,626,179) comes due Oct 21, 2027. Unpaid by Apr 21, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
PatentTitleStatus Expires Confidence
US 11,447,555Methods for treating type 1 diabetes using glucagon receptor antagonistic antibodies
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,752,693Methods for treating obesity and nonalcoholic fatty liver disease or nonalcoholic steatohepatitis using glucagon receptor antagonistic antibodies
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,626,179Methods for treating type 1 diabetes using glucagon receptor antagonistic antibodies
In force
 · From the USPTO record
In forceFrom the USPTO record
US 11,446,376Methods for treating heart failure using glucagon receptor antagonistic antibodies
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,765,737Methods for treating heart failure using glucagon receptor antagonistic antibodies
In force
 · From the USPTO record
In forceFrom the USPTO record
US 11,319,376Combination of glucagon receptor antagonists and PI3K pathway inhibitors for the treatment of cancer
In force
 · From the USPTO record
In forceFrom the USPTO record
US 11,248,049Immunotherapy using antibodies that bind Programmed Death 1 (PD-1)
In force
 · From the USPTO record
In forceFrom the USPTO record
US 11,332,531Immunotherapy using antibodies that bind programmed death ligand-1 (PD-L1)
In force
 · From the USPTO record
In forceFrom the USPTO record
US 11,242,398Anti-OX40 antibodies and methods of activating OX40
In force
 · From the USPTO record
In forceFrom the USPTO record
US 11,629,184Calcitonin gene-related peptide (CGRP) antagonist antibodies
In force
 · From the USPTO record
In forceFrom the USPTO record
10 of 12 patents shown.
Pro members see all 12.
Pro members: see all 12 patents
Also on record, not counted in the 12: 1 lapsed for an unpaid fee. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

1 pending · 6 no status recorded

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited